The primary business of the Group mainly focused on the development, manufacture and sales of proprietary biopharmaceutical products in cardiovascular and infectious diseases area During the 1990 s, the Group has developed three technology platforms, namely (i) the snake venom technology, and (iii) the low molecular weight heparin technology, and (iii) the water based gel delivery system The Group has equipped itself with GMP compliant workshops in Hefei, Anhui Province for the production of i bulk pharmaceutical for injection and lyophilized powder for injection, and (ii) gel.

Since the listing on the HKEx GEM in 2002 the Group has expanded its business operation and scope During the 2000 s, the Group has expanded its operations to include the commercialization of mature licensed in products from United States, Europe and other countries and has broadened its business scope to include other therapeutic areas such as paediatrics woman health, rare diseases, dermatology, obstetrics, urology, oncology and ophthalmology.

To date, the Group is fully integrated with strong infrastructures in drug development, regulatory, clinical development, manufacturing, sales and marketing based in mainland China with global perspectives. The Group has established extensive partnerships with over 20 international companies and currently markets 21 proprietary and licensed-in products in mainland China, Hong Kong, Macau and Taiwan. Lee's Pharm focuses on selected key disease areas such as cardiovascular, woman health, paediatrics, rare diseases, dermatology, obstetrics, urology, oncology, ophthalmology and others. As a R&D driven Company, the Group has more than 60 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various companies in the United States, Europe and other countries.